Hasnyálmirigyrák: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• KRAS 67
• PD-1 39
• TP53 4
• mTOR 0
• PI3K 0
• STAT3 0
• PD-L1 20
• CLDN18 21
• EGFR 11
• RAS 17
• BRCA2 8
• AKT 0
• BRCA1 10
• ERK 0
• MAPK 1
• PARP 9
• STING 0
• HER2 13
• MYC 0
• YAP 0
• MEK 5
• PALB2 9
• CTLA-4 9
• VEGF 3
• AMPK 0
• ATM 3
• CD40 2
• CXCR4 0
• HIF-1 0
• JNK 0
• NRF2 0
• CDKN2A 3
• GLP-1 2
• NRAS 5
• PRMT5 6
• IL-6 0
• PPAR 0
• PTEN 0
• BCL-2 0
• FAK 1
• IL-15 1
• JAK 0
• TROP2 3
• BRAF 2
• MET 2
• B7-H3 2
• CDK4/6 0
• FGFR 1
• HSP90 0
• CTNNB1 0
• HDAC 0
• KEAP1 1
• CD47 0
• METTL3 0
• MUC1 3
• AXL 1
• CCR5 0
• HER3 1
• NTRK 1
• RET 0

21+ intézményből 21, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Immunity under Pressure: Mapping Compression Driven Tumor–Immune Rewiring to Potentiate Immunotherapy in Pancreatic Cancer (MechanoImmunoMap)

  University of Cyprus· Nicosia, Ciprus· EU contribution 1 500 000 EUR· until 2032. jan.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Glycoengineering for Immune Modulation in Precision Anti-Cancer Therapies (GlycoIMPACT)

  Universitat Wien· Wien, Ausztria· EU contribution 230 185 EUR· until 2028. dec.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Next-Generation Radiopharmaceuticals for Glioblastoma and Pancreatic Cancer: A 3D Perspective (radio3D)

  Agencia Estatal Consejo Superior de Investigaciones Cientificas· Madrid, Spanyolország· EU contribution 4 366 500 EUR· until 2030. dec.· 9 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Evoking anti-tumor immunity in pancreatic cancer (Evoke-PDAC)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Németország· EU contribution 2 497 125 EUR· until 2031. dec.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Görögország· EU contribution 796 590 EUR· until 2030. dec.· 7 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Out-of-Distribution-aware Reasoning Agents for Clinical Learning and Exploration (ORACLE)

  Friedrich-Alexander-Universitaet Erlangen-Nuernberg· Erlangen, Németország· EU contribution 150 000 EUR· until 2028. jún.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Pancreatic juice-based Early Cancer Identification using Specific Epigenetics and (Glyco-)Proteomics – Advanced Next-generation Characterisation (PRECISE-PANC)

  Erasmus Universitair Medisch Centrum Rotterdam· Rotterdam, Hollandia· EU contribution 2 499 998 EUR· until 2031. dec.

• European Commission (Horizon Europe) · HORIZON-EIC

  Next generation therapeutic vaccine for targeted cancer treatment (VacciNEXT)

  Basinnov Life Sciences Unipessoal Lda· Lisboa, Portugália· EU contribution 2 827 529 EUR· until 2029. szept.· 3 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  AI-Driven Drug Discovery: Pancreatic Cancer Resistance via ENT1 Differential Conformation Tracking (PREDiCT-AI)

  The University of Sheffield· Sheffield, Egyesült Királyság· EU contribution 260 348 EUR· until 2028. szept.· 2 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  PERSONALISED NUTRITIONAL CARE FOR OLDER PATIENTS WITH LEUKAEMIA OR PANCREATIC CANCER – A PRAGMATIC IMPLEMENTATION TRIAL TO IMPROVE QUALITY OF LIFE (NutriCa65)

  Universitetet I Bergen· Bergen, Norvégia· EU contribution 5 296 543 EUR· until 2030. aug.· 9 countries

10 of 58 running projects, newest first. Listed amounts together: 177,8 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

  NCT05252390· Nuvation Bio Inc.· Frissítve: 2025. nov. 6.

  “The Sponsor has achieved its objectives.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors

  NCT04182516· Nerviano Medical Sciences· Frissítve: 2024. szept. 19.

  “The study closure is related to sponsor decision to shift towards the clinical development of NMS-03305293 in combination in a broader range of indication and not based on emerging safety or efficacy concerns.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

  NCT04858334· National Cancer Institute (NCI)· Forrás

• Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

  NCT04548752· National Cancer Institute (NCI)· Forrás

• Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC

  NCT07765836· Massachusetts General Hospital· Forrás

• A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway

  NCT06614751· Danatlas Pharmaceuticals Co., Ltd· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 50
• Organoids 47
• Mendelian Randomization Analysis 29
• CRISPR-Cas Systems 16
• Gene Expression Profiling 123
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 3
• Exome Sequencing 10
• Proteomics 55
• Metabolomics 34
• Mass Spectrometry 10
• Flow Cytometry 32
• Immunohistochemistry 70
• Liquid Biopsy 30
• Circulating Tumor DNA 29
• Xenograft Model Antitumor Assays 300
• Positron-Emission Tomography 30
• Magnetic Resonance Imaging 117
• Machine Learning 58
• Deep Learning 55
• Cohort Studies 108
• Genome-Wide Association Study 24

• Exploratory mendelian randomization of circulating metabolites and multi-omics characterization of ERCC1 in pancreatic cancer.

  Funct Integr Genomics, 2026. nov.

• Genetic evidence for associations between gastroesophageal reflux disease and site-specific extraesophageal cancers: A Mendelian randomization study.

  Medicine (Baltimore), 2026. okt.

• Unveiling the association between plasma lipid species and pan-cancers: A bidirectional 2-sample Mendelian randomization study.

  Medicine (Baltimore), 2026. szept.

• Exploration of the mechanism of gut microbiota-mediated immune modulation in the pathogenesis of pancreatic cancer: A Mendelian randomization study.

  Medicine (Baltimore), 2026. aug.

• Causal association between hip osteoarthritis and the risk of pancreatic cancer: A bidirectional two-sample Mendelian randomization study.

  Medicine (Baltimore), 2026. júl.

• New-Onset Type 2 Diabetes Mellitus and Cancer Risk: A Matched Cohort Study in China Kadoorie Biobank.

  Int J Cancer, 2026. júl.

• Genetic Links Between Cancer and Coronary Atherosclerosis: A Mendelian Randomization Analysis.

  Hum Mutat, 2026. júl.

• Causal Effects of Metabolic Factors on Pancreatic Ductal Adenocarcinoma Risk: A Mendelian Randomization Study.

  Niger Postgrad Med J, 2026. júl.

• CLEC4G Promotes Pancreatic Cancer Progression by Suppressing Cathepsin B-Mediated Ferroptosis: Evidence From Mendelian Randomization Study and Experimental Validation.

  Hum Mutat, 2026. jún.

• A Comprehensive Assessment of the Causal Relationship between Atopic Conditions and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomization Study.

  Cancer Epidemiol Biomarkers Prev, 2026. jún.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.